
    
      A study to evaluate the safety and effectiveness of experimental drugs ABT-450, ABT-267 (also
      known as ombitasvir), ABT-333 (also known as dasabuvir), ritonavir, and ribavirin in
      participants with HCV. The study will test the safety and effects of combinations of these
      drugs in treatments up to 24 weeks.
    
  